Physician profile
Michael Ruddy
NPI 1831138015
$1,134.18
in general payments reported to CMS, 2019-2025
17 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $122 · 2022: $30.76 · 2023: $194 · 2024: $298 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.76 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $306.24 | 2019-2025 | Jynarque |
| Amgen INC. | $194.89 | 2019-2025 | Tavneos, Krystexxa |
| Aurinia Pharma U.S., INC. | $111.71 | 2023-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $88.13 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $66.18 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $59.75 | 2023-2025 | |
| Vifor Pharma, INC. | $56.05 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $53.62 | 2024 | |
| Fresenius USA Marketing, INC. | $49.38 | 2019-2023 | Velphoro, Korsuva |
| Novo Nordisk INC | $39.05 | 2025 | Ozempic |
| Fresenius USA Manufacturing, INC. | $19.03 | 2023 | Velphoro, Korsuva |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.83 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.26 | 2025 | Jardiance |
| Lilly USA, LLC | $15.87 | 2023 | Jardiance |
| Travere Therapeutics, INC. | $13.97 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13.70 | 2022 | |
| Mallinckrodt Hospital Products INC. | $13.52 | 2025 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ruddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.